関連する実験動画
Updated: Feb 21, 2026

06:04
Source and Route of Pyrrolizidine Alkaloid Contamination in Tea Samples
Published on: September 28, 2022
2.5K
中国の製薬産業のサプライチェーンにおける尾部リスクの転移効果に関する研究
Cheng Wang1,2, Mengnan Xu1,2, Mengyue Xu1,2
1School of Pharmaceutical Economics and Management, Anhui University of Chinese Medicine, Hefei, China.
Frontiers in public health
|February 20, 2026
まとめ
中国 中国 中国 中国 中国.
科学分野:
- サプライチェーン管理とは
- 金融リスク分析 金融リスク分析
- 医薬品産業のダイナミクス
背景:
- 経済的な不確実性の高まりと極端な出来事により,製薬サプライチェーンの回復力に関する研究が求められています.
- 中国製薬業界の安全,安定,高品質の発展を保証することは,極めて重要な問題です.
研究 の 目的:
- 中国の製薬サプライチェーンの尾部リスクネットワークを分析するために.
- 構造的特徴,ダイナミックなパターン,リスクの転移効果を検証する.
- 鍵となる機関を特定し,様々なテールリスクイベントの下でのリスク伝播を理解する.
主な方法:
- TENET (テール・イベント・エクスプロイト・ネットワーク) メソッドを使用した.
- 製薬サプライチェーンのテールリスクネットワーク (2012-2023) を構築しました.
- 構造的特徴,時間的動態,および全体,モジュール,および機関レベルでリスクの転移効果を分析した.
主要な成果:
- 尾部リスクは時間によって変化し,リスクイベントの間に総接続性が増加します.
- 生産モジュールは主なリスク源であり,生産および流通モジュールは,クラスター化された溢出効果を示しています.
- ヘングルー製薬,アイアール眼科医院,およびフォソンファーマはシステム的に重要であり,金融危機は公衆衛生の出来事とは異なり,リスクを高めます.
結論:
- テイルイベントは,医薬品サプライチェーンにおけるリスク伝播頻度を普遍的に増加させる.
- ネットワークトポロジーの理解は,サプライチェーンの回復力を高めるために不可欠です.
- 将来の研究は,より深い洞察を得るために,高度なエコノメトリックと因果的発見技術を探求すべきである.
関連する概念動画
Pharmaceutical Poisoning: Potential Scenarios
20
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
20
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
197
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
197
Pharmacovigilance
1.8K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.8K
Drug Control Governance: Regulatory Bodies and Their Impact
592
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
592
FDA Approved Drugs: Changes to Approved Drugs
286
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
286
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
25
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
25
